OrthoPediatrics Corp. has announced impressive financial results for the third quarter of 2026, showcasing significant growth and a positive outlook for the remainder of the year. The company reported record revenue of $72.7 million, marking a 19% increase compared to the same period last year. This strong performance has led OrthoPediatrics to raise its full-year revenue guidance, reflecting confidence in its business strategy and market position.

Based in Warsaw, Indiana, OrthoPediatrics Corp. specializes in surgical and medical instruments and apparatus, particularly focusing on pediatric orthopedics. The company trades on the Nasdaq under the ticker symbol KIDS and is categorized as an accelerated filer. Recent filings include an 8-K submitted on October 27, 2026, detailing its financial results and other disclosures.

In the recent filing, OrthoPediatrics disclosed, "On October 27, 2026, OrthoPediatrics Corp. issued a press release announcing its earnings for the quarter ended September 30, 2026 and making other disclosures." The company highlighted that it helped nearly 42,000 children during the quarter and achieved a record adjusted EBITDA of $6.9 million.

The results are expected to impact various stakeholders, including healthcare providers, patients, and investors. The increase in revenue and guidance suggests a growing demand for OrthoPediatrics' products, which could enhance its competitive position within the surgical and medical instruments industry.

Looking ahead, OrthoPediatrics aims to continue its growth trajectory by launching new products and expanding its market share. The filing does not specify the next steps, but the company’s strong quarterly performance indicates that it is well-positioned for future success.